Navigation Links
GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.
Date:1/22/2013

PISCATAWAY, N.J., Jan. 22, 2013 /PRNewswire/ -- GenScript and Open Monoclonal Technology, Inc. (OMT) today announced a joint road show with potential clients across the US, China, Japan and South Korea in late January and early February. The road show will offer prospective clients introductions to GenScript and OMT's human antibody discovery technologies and explore new ways of accelerated and improved development of this important class of human therapeutics.

GenScript

GenScript offers a full spectrum of human antibody services, including target screening and expression, immunization, monoclonal antibody screening at any desired high complexity, antibody sequencing and characterization, biological and other assays, antibody production cell line development, model animal-based efficacy studies and more. GenScript's antibody development team consists of senior scientists and business managers who have extensive experience in therapeutic antibody development. They have been involved in the full process of therapeutic drug development. GenScript has already successfully gained a top position in gene synthesis worldwide, and has established leading positions in many other biology service areas.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – naturally optimized human antibodies™. OMT has created OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat™ uses an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables them to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat™ represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications. OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat™ and further increase epitope coverage in human antibody development. OmniAb™ integrates OMT's transgenic animal platforms, proven protein- and DNA-mediated immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.

Web site: www.genscript.com

 


'/>"/>
SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
2. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
3. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
4. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
5. TNI BioTech, Inc. Announces Appointment of New CFO
6. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
7. BioDelivery Sciences Announces Completion of BNX Safety Study
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
11. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/28/2017)... San Mateo, CA (PRWEB) , ... April 28, 2017 , ... ... Bay Area cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to ... tags allow interested persons to bookmark and read organized content on topics such as ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American ... 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list ... Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney General ...
(Date:4/27/2017)... Malibu, CA (PRWEB) , ... April 27, 2017 , ... ... United States with an oil many times purer and more potent than the market ... mountain air of Gstaad, Switzerland, as well as a patented chromatography process for extraction, ...
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
Breaking Medicine News(10 mins):